Dalteparin sodium-induced thrombocytopenia and arterial thrombosis
10.3760/cma.j.cn114015-20210318-00323
- VernacularTitle:达肝素钠引起血小板减少合并动脉血栓形成
- Author:
Hongming LIU
1
;
Jian WANG
1
;
Zheng DING
1
Author Information
1. 重庆医科大学附属南川人民医院药剂科，重庆 408400
- Publication Type:Journal Article
- Keywords:
Dalteparin;
Thrombocytopenia;
Thrombosis;
Iliac artery
- From:
Adverse Drug Reactions Journal
2022;24(1):44-46
- CountryChina
- Language:Chinese
-
Abstract:
A 64-year-old male patient underwent laparoscopic radical cystectomy for bladder squamous cell carcinoma, followed by anticoagulant therapy with subcutaneous injection of dalteparin sodium injection 5 000 U once daily. On the 8th day of dalteparin sodium treatment, the patient developed thrombocytopenia [platelet count (PLT) decreased from 132×10 9/L before operation to 65×10 9/L after operation]; on the 10th day, the patient developed weakness, swelling, and low skin temperature and cyanosis in the left thigh. Laboratory tests showed PLT 22×10 9/L and positive serum heparin/platelet factor 4 complex antibody. CT angiography of the left lower limb showed thrombosis of the left arteria iliaca communis. Heparin-induced thrombocytopenia with thrombosis was diagnosed. Dalteparin sodium was discontinued and replaced by subcutaneous injection of fondaparinux sodium 7.5 mg once daily. Two days later, the swelling in the left thigh was relieved and PLT was 62×10 9/L; 8 days later, the swelling of left lower limb subsided and PLT was 128×10 9/L; 18 days later, CT angiography of the left lower limb showed that the location of thrombus in the left arteria iliaca communis was partially recanalized and PLT was 185×10 9/L.
